Chinese Drug Regulators Issue New Rules To Increase Safety Standards Of Vaccines
This article was originally published in PharmAsia News
Executive Summary
BEIJING - In the wake of a series of vaccine scandals across China during the past year, triggering sometimes fatal adverse events, China's State FDA is strengthening rules governing the manufacturing, distribution and inspection of vaccines nationwide
You may also be interested in...
Are China’s Vaccines Ready For The World?
With WHO approval in hand, China’s vaccine industry looks to take the next step into global markets.
What Multinational Companies Need To Know About China's New GMP Regs - Webinar (Part 2 of 2)
SHANGHAI - China's new good manufacturing practices regulations that went into effect March 1 significantly raise drug manufacturing standards in almost all areas, and shift the focus of China GMPs to a risk-based quality approach. But more importantly, the new regs indicate how China's State FDA views GMPs and the specific areas that will see more regulatory focus
What Multinational Companies Need To Know About China's New GMP Regs - Webinar (Part 2 of 2)
SHANGHAI - China's new good manufacturing practices regulations that went into effect March 1 significantly raise drug manufacturing standards in almost all areas, and shift the focus of China GMPs to a risk-based quality approach. But more importantly, the new regs indicate how China's State FDA views GMPs and the specific areas that will see more regulatory focus